Melatonin in Glaucoma: Integrative Mechanisms of Intraocular Pressure Control and Neuroprotection

Biomedicines, Journal Year: 2025, Volume and Issue: 13(5), P. 1213 - 1213

Published: May 16, 2025

Background: Glaucoma is a leading cause of irreversible visual loss worldwide, characterized by progressive retinal ganglion cell (RGC) degeneration and optic nerve damage. Current therapies mainly focus on lowering intraocular pressure (IOP), yet fail to address pressure-independent neurodegenerative mechanisms. Melatonin, an endogenously produced indoleamine, has gained attention for its potential in modulating both IOP neurodegeneration through diverse cellular pathways. This review evaluates the therapeutic relevance melatonin glaucoma examining mechanistic actions emerging delivery approaches. Methods: A comprehensive literature search was conducted via PubMed Medline identify studies published between 2000 2025 melatonin's roles glaucoma. Included articles discussed effects regulation, RGC survival, oxidative stress, mitochondrial integrity, inflammation. Results: Evidence supports involvement reduction MT receptor activation synergism with adrenergic enzymatic regulators. Moreover, it protects RGCs mitigating preventing dysfunction, inhibiting apoptotic inflammatory cascades. Recent advances ocular drug systems enhance bioavailability potential. Conclusions: Melatonin represents multi-target candidate treatment. Further clinical are necessary establish optimal dosing strategies, methods, long-term safety patients.

Language: Английский

Inhibition of mitochondrial over-division by (+)-14,15-Dehydrovincamine attenuates cisplatin-induced acute kidney injury via the JNK/Mff pathway

Free Radical Biology and Medicine, Journal Year: 2024, Volume and Issue: 224, P. 190 - 203

Published: Aug. 27, 2024

Language: Английский